Corcept Reiterates 2026 Revenue Guidance of $1.1B-$1.2B
Corcept Therapeutics reiterated its 2026 revenue guidance of $1.1B-$1.2B, versus a FactSet estimate of $1.15B.
Related stories
SK Telecom Operating Profit Rises 1,040.3%
SK Telecom reported consolidated operating profit for Q3 2026, up 1,040.3% year over year.
M impact | EARNINGS | Nov 04, 2026, 12:54 AM UTC
SK Telecom Operating Income Jumps 1,040.3% to KRW 552.3 Billion
M impact | EARNINGS | Nov 04, 2026, 12:54 AM UTC
SK Telecom 3Q Revenue KRW4.497T vs. KRW3.978T
M impact | EARNINGS | Nov 04, 2026, 12:47 AM UTC
SK Telecom Swings to Operating Profit in Q3
SK Telecom’s standalone Q3 2026 operating profit was 413.5십억 won, a year-earlier swing to profitability. Revenue was 3.16조 won.
M impact | EARNINGS | Nov 04, 2026, 12:44 AM UTC
AMD Sales Forecast Tops Expectations; Shares Rise
AMD’s sales outlook exceeded expectations, easing concerns about AI investment.
L impact | EARNINGS | Nov 04, 2026, 12:34 AM UTC
Booking Holdings Sees Resilient Travel Demand Despite Disruptions
Booking Holdings said travel demand remains resilient, though the company fell short of third-quarter revenue expectations.
L impact | EARNINGS | Nov 04, 2026, 12:32 AM UTC